Haleon Surprises Analysts With Stand-Out Cold & Flu Showing In Q4
Executive Summary
In describing Haleon’s Q4 showing as a “strong finish to the year,” Bernstein’s Bruno Monteyne pointed to “remarkable strength in respiratory health,” with the category resoundingly beating analysts’ consensus estimates of a 2.5% decline.